Overview

Globally, the diagnosis of metabolic diseases such as type 2 diabetes and obesity has increased. Since the COVID-19 pandemic, the global prevalence of obesity has worsened. Obesity is considered a main precursor of diabetes and contributes an estimated 80% to 85% toward the risk of type 2 diabetes. As a result, the financial burden associated with healthcare has grown and is predicted to continue.

The demand for combination treatments that address obesity and diabetes (diabesity) jointly has increased notably as a result of these healthcare challenges. Current drug therapies for obesity have a limited safety and efficacy profile. Furthermore, patient-centricity and variability in disease management are lacking. These gaps in available therapies will lead to increased demand for newer classes of drugs, such as GLP-1 receptor agonists.

• What has emerged as a breakthrough drug class and offers superior glycemic control and weight loss, resulting in better clinical outcomes and growth?
• How can your team improve supply, affordability, and access to therapies, prevent off-label sales, and drive the growth of direct-to-consumer and hybrid care models?
• How can life science companies capitalize on key competitive differentiation and growth strategies that focus on lowering the dosing frequency, sustained weight loss without lean muscle loss, benefits across the cardiometabolic spectrum, and drug delivery innovations?

Quick links

Click here to preview this analysis

Already a member? Click here to access the analysis